JP2023519891A5 - - Google Patents
Info
- Publication number
- JP2023519891A5 JP2023519891A5 JP2022558424A JP2022558424A JP2023519891A5 JP 2023519891 A5 JP2023519891 A5 JP 2023519891A5 JP 2022558424 A JP2022558424 A JP 2022558424A JP 2022558424 A JP2022558424 A JP 2022558424A JP 2023519891 A5 JP2023519891 A5 JP 2023519891A5
- Authority
- JP
- Japan
- Prior art keywords
- approximately
- compound
- pharmaceutical composition
- crystalline form
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (31)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063000746P | 2020-03-27 | 2020-03-27 | |
| US63/000,746 | 2020-03-27 | ||
| US202063015241P | 2020-04-24 | 2020-04-24 | |
| US63/015,241 | 2020-04-24 | ||
| US202063018954P | 2020-05-01 | 2020-05-01 | |
| US63/018,954 | 2020-05-01 | ||
| US202063022301P | 2020-05-08 | 2020-05-08 | |
| US202063022298P | 2020-05-08 | 2020-05-08 | |
| US63/022,298 | 2020-05-08 | ||
| US63/022,301 | 2020-05-08 | ||
| US202063024160P | 2020-05-13 | 2020-05-13 | |
| US63/024,160 | 2020-05-13 | ||
| US202063053903P | 2020-07-20 | 2020-07-20 | |
| US63/053,903 | 2020-07-20 | ||
| US202063076689P | 2020-09-10 | 2020-09-10 | |
| US63/076,689 | 2020-09-10 | ||
| US202063126173P | 2020-12-16 | 2020-12-16 | |
| US63/126,173 | 2020-12-16 | ||
| US202063128523P | 2020-12-21 | 2020-12-21 | |
| US63/128,523 | 2020-12-21 | ||
| US202163136080P | 2021-01-11 | 2021-01-11 | |
| US63/136,080 | 2021-01-11 | ||
| US202163136967P | 2021-01-13 | 2021-01-13 | |
| US63/136,967 | 2021-01-13 | ||
| US202163138672P | 2021-01-18 | 2021-01-18 | |
| US63/138,672 | 2021-01-18 | ||
| US202163140116P | 2021-01-21 | 2021-01-21 | |
| US63/140,116 | 2021-01-21 | ||
| US202163149230P | 2021-02-13 | 2021-02-13 | |
| US63/149,230 | 2021-02-13 | ||
| PCT/US2021/024316 WO2021195475A1 (en) | 2020-03-27 | 2021-03-26 | Process, compositions, and crystalline forms of substituted pyridinone-pyridinyl compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023519891A JP2023519891A (ja) | 2023-05-15 |
| JP2023519891A5 true JP2023519891A5 (cg-RX-API-DMAC7.html) | 2024-03-29 |
Family
ID=77890611
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022558424A Pending JP2023519891A (ja) | 2020-03-27 | 2021-03-26 | 置換ピリジノン-ピリジニル化合物のプロセス、組成物、および結晶形態 |
| JP2022558423A Pending JP2023519890A (ja) | 2020-03-27 | 2021-03-26 | 免疫状態の処置のためのmk2経路阻害剤の経口組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022558423A Pending JP2023519890A (ja) | 2020-03-27 | 2021-03-26 | 免疫状態の処置のためのmk2経路阻害剤の経口組成物 |
Country Status (12)
| Country | Link |
|---|---|
| US (5) | US12616696B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP4132524A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2023519891A (cg-RX-API-DMAC7.html) |
| KR (2) | KR20220161390A (cg-RX-API-DMAC7.html) |
| CN (4) | CN119454711A (cg-RX-API-DMAC7.html) |
| AU (2) | AU2021244609A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022019349A2 (cg-RX-API-DMAC7.html) |
| CA (2) | CA3172088A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL296054A (cg-RX-API-DMAC7.html) |
| MX (2) | MX2022011755A (cg-RX-API-DMAC7.html) |
| PH (2) | PH12022552263A1 (cg-RX-API-DMAC7.html) |
| WO (3) | WO2021195507A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL296054A (en) * | 2020-03-27 | 2022-10-01 | Aclaris Therapeutics Inc | Oral compositions of mk2 pathway inhibitor for treatment of immune conditions |
| WO2022020562A1 (en) * | 2020-07-24 | 2022-01-27 | Bristol-Myers Squibb Company | Methods of treating acute respiratory disorders |
| KR20230112696A (ko) * | 2020-11-23 | 2023-07-27 | 어클라리스 쎄라퓨틱스, 인코포레이티드 | 치환된 피리디논-피리디닐 화합물의 합성 방법 |
| WO2022212489A1 (en) | 2021-03-31 | 2022-10-06 | Xinthera, Inc. | Mk2 inhibitors and uses thereof |
| US11685719B2 (en) | 2021-07-09 | 2023-06-27 | Xinthera, Inc. | Pyridinone MK2 inhibitors and uses thereof |
| WO2023125708A1 (zh) * | 2021-12-29 | 2023-07-06 | 上海美悦生物科技发展有限公司 | 一种p38 MAPK/MK2通路调节剂及其组合物、制备方法和用途 |
| CN116396274B (zh) * | 2022-01-06 | 2025-11-11 | 深圳信立泰药业股份有限公司 | 一种取代的联吡啶酮类化合物及其制备方法与应用 |
| CN116444493A (zh) * | 2022-01-14 | 2023-07-18 | 上海翰森生物医药科技有限公司 | 含双并环类衍生物、其制备方法和应用 |
| US20230286950A1 (en) * | 2022-02-04 | 2023-09-14 | Aclaris Therapeutics, Inc. | Methods of synthesizing deuterated substituted pyridinone-pyridinyl compounds |
| CN120076802A (zh) * | 2022-09-30 | 2025-05-30 | 艾伯维公司 | 治疗化脓性汗腺炎的方法 |
| CN118047757A (zh) * | 2022-11-16 | 2024-05-17 | 上海美悦生物科技发展有限公司 | 吡啶氮氧化物类衍生物及其药物组合物、制备方法和用途 |
| KR20240078816A (ko) | 2022-11-28 | 2024-06-04 | 주식회사 엘지에너지솔루션 | 에이징 시스템 |
| US20260217652A1 (en) | 2023-01-13 | 2026-07-30 | Shanghai Meiyue Biotech Development Co., Ltd. | Phenyl-substituted heteroaryl compound and pharmaceutical composition comprising same, preparation method therefor and use thereof |
| JP2026504073A (ja) * | 2023-01-13 | 2026-02-03 | プールベグ ファーマ(ユーケー) リミテッド | がん免疫療法関連サイトカイン放出症候群の軽減のための医薬品および方法 |
| WO2025093869A1 (en) * | 2023-11-01 | 2025-05-08 | Poolbeg Pharma (UK) Limited | P38 map kinase inhibitor for use in the treatment of inflammation |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4166452A (en) | 1976-05-03 | 1979-09-04 | Generales Constantine D J Jr | Apparatus for testing human responses to stimuli |
| US4256108A (en) | 1977-04-07 | 1981-03-17 | Alza Corporation | Microporous-semipermeable laminated osmotic system |
| US4265874A (en) | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
| AU762245B2 (en) | 1998-09-18 | 2003-06-19 | Vertex Pharmaceuticals Incorporated | Inhibitors of p38 |
| HUP0201261A3 (en) | 1999-05-21 | 2003-12-29 | Scios Inc Sunnyvale | Indole-type derivatives as inhibitors of p38 kinase and pharmaceutical compositions containing them |
| IL150524A0 (en) | 2000-01-07 | 2003-02-12 | Transform Pharmaceuticals Inc | High-throughput formation, identification, and analysis of diverse solid-forms |
| AU2002226911A1 (en) | 2000-11-20 | 2002-06-03 | Scios Inc. | Indol derivative and their use as inhibitors of p38 kinase |
| US7314752B2 (en) | 2001-07-19 | 2008-01-01 | Common Sense, Ltd. | Secretion-monitoring article |
| AP1822A (en) | 2002-02-14 | 2008-01-30 | Pharmacia Corp | Substituted pyridinones as modulators of P38 MAP kinase. |
| EP1506189A1 (en) | 2002-04-26 | 2005-02-16 | Vertex Pharmaceuticals Incorporated | Pyrrole derivatives as inhibitors of erk2 and uses thereof |
| GB0218630D0 (en) | 2002-08-10 | 2002-09-18 | Tanabe Seiyaku Co | Novel compounds |
| WO2004024078A2 (en) | 2002-09-11 | 2004-03-25 | Merck & Co., Inc. | Dihydroxypyridopyrazine-1,6-dione compounds useful as hiv integrase inhibitors |
| US20070167621A1 (en) | 2003-04-03 | 2007-07-19 | Pharmacia Corporation | Substituted pyrimidinones |
| US7183287B2 (en) | 2003-04-03 | 2007-02-27 | Pharmacia Corporation | Substituted pyrimidinones |
| CL2004002050A1 (es) | 2003-08-13 | 2005-06-03 | Pharmacia Corp Sa Organizada B | Compuestos derivados de piridinonas sustituidas; su uso en el tratamiento de afecciones causadas o exacerbadas por actividad p38 map kinasa y/o tnf no regulada, tales como inflamaciones, tumores, sida y otros. |
| US20060014741A1 (en) * | 2003-12-12 | 2006-01-19 | Dimarco John D | Synthetic process, and crystalline forms of a pyrrolotriazine compound |
| GB0402653D0 (en) * | 2004-02-06 | 2004-03-10 | Cyclacel Ltd | Compounds |
| JP2005255675A (ja) | 2004-02-09 | 2005-09-22 | Tanabe Seiyaku Co Ltd | 医薬組成物 |
| CN1976915A (zh) | 2004-02-11 | 2007-06-06 | 史密丝克莱恩比彻姆公司 | Hiv整合酶抑制剂 |
| US7936407B2 (en) | 2005-02-24 | 2011-05-03 | Samsung Electronics Co., Ltd. | Array substrate, method of manufacturing the same, display panel having the same, and liquid crystal display apparatus having the same |
| RU2007141401A (ru) | 2005-04-08 | 2009-05-20 | ЭЙСАЙ Ар энд Ди МЕНЕДЖМЕНТ КО., ЛТД. (JP) | Терапевтический агент для лечения дискинезии |
| TW200740755A (en) | 2005-07-13 | 2007-11-01 | Bayer Cropscience Sa | Dihalogenation of N,O-disubstituted hydroxypyridones and their uses |
| WO2007081901A2 (en) | 2006-01-05 | 2007-07-19 | The Scripps Research Institute | Pyrimidinone derivatives as protein kinase inhibitors |
| PE20080150A1 (es) | 2006-06-02 | 2008-04-11 | Janssen Pharmaceutica Nv | Derivados de piridinona n-aril y n-heteroaril sustituidos como antagonistas del receptor de la hormona concentradora de melanina (mch) |
| AU2007272830B2 (en) | 2006-07-14 | 2011-07-28 | Amgen Inc. | Alkyne-substituted pyridone compounds and methods of use |
| EA200970510A1 (ru) | 2006-11-24 | 2009-12-30 | Такеда Фармасьютикал Компани Лимитед | Гетеромоноциклическое соединение и его применение |
| BRPI0720049A2 (pt) | 2006-12-07 | 2014-01-07 | Novartis Ag | Derivados de piridina utilizados como inibidores de xiap |
| US20110130403A1 (en) * | 2007-03-14 | 2011-06-02 | Ranbaxy Laboratories Limited | Pyrazolo [3, 4-b] pyridine derivatives as phosphodiesterase inhibitors |
| JP2010529129A (ja) | 2007-06-06 | 2010-08-26 | タイロジェネックス,インコーポレイテッド | キナーゼ阻害剤化合物 |
| PL2170864T3 (pl) | 2007-07-17 | 2012-02-29 | Bristol Myers Squibb Co | Agoniści receptora gpr119 sprężonego z białkiem g - pirydon |
| WO2009156484A2 (en) | 2008-06-27 | 2009-12-30 | Novartis Ag | Organic compounds |
| WO2010025202A1 (en) * | 2008-08-29 | 2010-03-04 | Amgen Inc. | PYRIDO[3,2-d]PYRIDAZINE-2(1H)-ONE COMPOUNDS AS P38 MODULATORS AND METHODS OF USE THEREOF |
| CA2763565A1 (en) | 2009-05-28 | 2010-12-02 | Novartis Ag | Substituted aminobutyric derivatives as neprilysin inhibitors |
| US8629158B2 (en) | 2009-07-01 | 2014-01-14 | Albany Molecular Research, Inc. | Azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine MCH-1 antagonists, methods of making, and use thereof |
| WO2011003012A1 (en) | 2009-07-01 | 2011-01-06 | Albany Molecular Research, Inc. | Azinone-substituted azapolycycle mch-1 antagonists, methods of making, and use thereof |
| WO2011003021A1 (en) | 2009-07-01 | 2011-01-06 | Albany Molecular Research, Inc. | Azinone-substituted azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine mch-1 antagonists, methods of making, and use thereof |
| AU2010302420B2 (en) * | 2009-10-02 | 2013-07-04 | Astrazeneca Ab | 2-pyridone compounds used as inhibitors of neutrophil elastase |
| DK2648516T3 (da) * | 2010-12-06 | 2019-01-02 | Aclaris Therapeutics Inc | Substituerede pyridinon-pyridinylforbindelser |
| US9056110B2 (en) | 2011-12-06 | 2015-06-16 | Confluence Life Sciences, Inc. | Substituted pyrimidinone-phenyl-pyrimidinyl compounds |
| KR102313515B1 (ko) | 2013-06-07 | 2021-10-14 | 어클라리스 쎄라퓨틱스, 인코포레이티드 | 메틸/플루오로-피리디닐-메톡시 치환된 피리디논-피리디닐 화합물 및 플루오로-피리미디닐-메톡시 치환된 피리디논-피리디닐 화합물 |
| WO2015161908A1 (en) * | 2014-03-11 | 2015-10-29 | Ludwig-Maximilians-Universität München | Non-immunosuppressive cyclophilin inhibitors for the treatment of coronavirus infections |
| CN114230571B (zh) * | 2015-09-14 | 2025-07-08 | 无限药品股份有限公司 | 异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法 |
| CN111727042A (zh) | 2017-12-06 | 2020-09-29 | 仁新医药私人有限公司 | 微管蛋白抑制剂 |
| CN114206339A (zh) * | 2019-07-31 | 2022-03-18 | 阿克拉瑞斯治疗股份有限公司 | 氘化mk2途径抑制剂及其使用方法 |
| WO2021178449A1 (en) | 2020-03-02 | 2021-09-10 | Washington University | Compositions and methods for the treatment of pancreatic cancer |
| IL296054A (en) | 2020-03-27 | 2022-10-01 | Aclaris Therapeutics Inc | Oral compositions of mk2 pathway inhibitor for treatment of immune conditions |
-
2021
- 2021-03-26 IL IL296054A patent/IL296054A/en unknown
- 2021-03-26 EP EP21776610.4A patent/EP4132524A4/en not_active Withdrawn
- 2021-03-26 PH PH1/2022/552263A patent/PH12022552263A1/en unknown
- 2021-03-26 PH PH1/2022/552321A patent/PH12022552321A1/en unknown
- 2021-03-26 JP JP2022558424A patent/JP2023519891A/ja active Pending
- 2021-03-26 JP JP2022558423A patent/JP2023519890A/ja active Pending
- 2021-03-26 AU AU2021244609A patent/AU2021244609A1/en not_active Abandoned
- 2021-03-26 KR KR1020227037183A patent/KR20220161390A/ko not_active Withdrawn
- 2021-03-26 MX MX2022011755A patent/MX2022011755A/es unknown
- 2021-03-26 CN CN202411390540.5A patent/CN119454711A/zh active Pending
- 2021-03-26 US US17/907,514 patent/US12616696B2/en active Active
- 2021-03-26 AU AU2021244255A patent/AU2021244255A1/en not_active Abandoned
- 2021-03-26 CN CN202411432060.0A patent/CN119235863A/zh active Pending
- 2021-03-26 US US17/214,532 patent/US11844801B2/en active Active
- 2021-03-26 BR BR112022019349A patent/BR112022019349A2/pt not_active Application Discontinuation
- 2021-03-26 EP EP21775856.4A patent/EP4125891A4/en not_active Withdrawn
- 2021-03-26 US US17/907,516 patent/US20230149400A1/en active Pending
- 2021-03-26 MX MX2022011748A patent/MX2022011748A/es unknown
- 2021-03-26 CA CA3172088A patent/CA3172088A1/en active Pending
- 2021-03-26 CN CN202180032410.2A patent/CN115484952B/zh not_active Expired - Fee Related
- 2021-03-26 WO PCT/US2021/024376 patent/WO2021195507A1/en not_active Ceased
- 2021-03-26 CN CN202180037711.4A patent/CN115666566A/zh active Pending
- 2021-03-26 WO PCT/US2021/024316 patent/WO2021195475A1/en not_active Ceased
- 2021-03-26 WO PCT/US2021/024482 patent/WO2021195562A1/en not_active Ceased
- 2021-03-26 CA CA3172203A patent/CA3172203A1/en active Pending
- 2021-03-26 KR KR1020227037292A patent/KR20220161396A/ko not_active Withdrawn
-
2023
- 2023-11-08 US US18/504,778 patent/US12370195B2/en active Active
-
2025
- 2025-06-25 US US19/249,611 patent/US20250387393A1/en active Pending